Berman B A, Fenton M M, Girsch L S, Haddad Z H, Sellars W A, Strem E L, Thompson H C, Wall L E
Pediatrics. 1975 May;55(5):621-9.
Cromolyn sodium is a recently introduced drug used in the prophylactic treatment of severe, perennial, bronchial asthma, particularly in the pediatric age group. In a multicenter trial, 276 chronic asthmatic patients of eight pediatric allergists entered a randomized, double-blind, placebo-controlled, crossover study lasting 12 weeks. Test compounds of cromolyn sodium or placebo were inhaled four times a day, and daily scores were kept of symptom severity as well as frequency of use of other medications. Patients had statistically significant lower average daily symptom scores when treated with cromolyn sodium as compared to treatment with placebo. A strong subjective preference for cromolyn sodium was expressed by 60% of those completing the trial, versus 9% for placebo. The patients' need for other symptomatic medications also dropped significantly during the cromolyn treatment period.
色甘酸钠是一种最近引入的药物，用于重度、常年性支气管哮喘的预防性治疗，尤其是在儿童年龄组。在一项多中心试验中，来自八位儿科过敏症专家的276名慢性哮喘患者进入了一项为期12周的随机、双盲、安慰剂对照、交叉研究。色甘酸钠或安慰剂的测试化合物每天吸入四次，并记录症状严重程度以及其他药物使用频率的每日评分。与使用安慰剂治疗相比，使用色甘酸钠治疗的患者平均每日症状评分在统计学上显著更低。完成试验的患者中有60%对色甘酸钠表现出强烈的主观偏好，而对安慰剂的偏好为9%。在色甘酸钠治疗期间，患者对其他对症药物的需求也显著下降。
